Geode Capital Management LLC Purchases 11,411 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS)

Geode Capital Management LLC raised its stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 2.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 591,631 shares of the company's stock after buying an additional 11,411 shares during the period. Geode Capital Management LLC owned 2.06% of Krystal Biotech worth $107,714,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Key Financial Inc bought a new stake in shares of Krystal Biotech during the 2nd quarter worth $28,000. Blue Trust Inc. lifted its position in Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company's stock worth $30,000 after acquiring an additional 163 shares during the last quarter. Values First Advisors Inc. bought a new stake in Krystal Biotech during the third quarter valued at about $53,000. Quest Partners LLC acquired a new stake in shares of Krystal Biotech in the second quarter valued at about $71,000. Finally, GAMMA Investing LLC increased its stake in shares of Krystal Biotech by 184.8% in the third quarter. GAMMA Investing LLC now owns 430 shares of the company's stock worth $78,000 after purchasing an additional 279 shares during the period. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Stock Up 2.7 %

KRYS traded up $4.19 during trading on Thursday, reaching $160.83. 457,565 shares of the company's stock were exchanged, compared to its average volume of 323,257. The company has a market capitalization of $4.63 billion, a P/E ratio of 90.86 and a beta of 0.80. The business has a 50 day moving average price of $180.70 and a 200 day moving average price of $185.17. Krystal Biotech, Inc. has a fifty-two week low of $107.50 and a fifty-two week high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.84 by $0.07. The firm had revenue of $83.84 million for the quarter, compared to analysts' expectations of $82.94 million. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The business's revenue was up 879.9% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.67) earnings per share. As a group, research analysts forecast that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Analysts Set New Price Targets

Several brokerages recently weighed in on KRYS. HC Wainwright restated a "buy" rating and set a $221.00 target price on shares of Krystal Biotech in a research note on Wednesday. Stifel Nicolaus increased their price objective on Krystal Biotech from $204.00 to $220.00 and gave the company a "buy" rating in a research report on Wednesday, September 11th. Citigroup raised their price objective on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Finally, Chardan Capital restated a "buy" rating and issued a $212.00 price target on shares of Krystal Biotech in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $206.67.

Insider Activity at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the sale, the insider now directly owns 1,475,882 shares in the company, valued at $243,195,835.96. This represents a 1.67 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 14.10% of the stock is currently owned by insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).